HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 6, 3688-3694, February 9, 2007

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 282/6/3688    most recent M610271200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by He, J. Q. Articles by Cheng, G. Search for Related Content PubMed PubMed Citation Articles by He, J. Q. Articles by Cheng, G. Social Bookmarking                      What's this?

Specificity of TRAF3 in Its Negative Regulation of the Noncanonical NF-B Pathway^*

Jeannie Q. He¹, Supriya K. Saha², Jason R. Kang, Brian Zarnegar³, and Genhong Cheng^¶4

From the Department of Microbiology, Immunology, and Molecular Genetics, the Medical Scientist Training Program, and ^¶Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095

Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are critical signaling adaptors downstream of many receptors in the TNF receptor and interleukin-1 receptor/Toll-like receptor superfamilies. Whereas TRAF2, 5, and 6 are activators of the canonical NF-B signaling pathway, TRAF3 is an inhibitor of the noncanonical NF-B pathway. The contribution of the different domains in TRAFs to their respective functions remains unclear. To elucidate the structural and functional specificities of TRAF3, we reconstituted TRAF3-deficient cells with a series of TRAF3 mutants and assessed their abilities to restore TRAF3-mediated inhibition of the noncanonical NF-B pathway as measured by NF-B-inducing kinase (NIK) protein levels and processing of p100 to p52. We found that a structurally intact RING finger domain of TRAF3 is required for inhibition of the noncanonical NF-B pathway. In addition, the three N-terminal domains, but not the C-terminal TRAF domain, of the highly homologous TRAF5 can functionally replace the corresponding domains of TRAF3 in suppression of the noncanonical NF-B pathway. This functional specificity correlates with the specific binding of TRAF3, but not TRAF5, to the previously reported TRAF3 binding motif in NIK. Our studies suggest that both the RING finger domain activity and the specific binding of the TRAF domain to NIK are two critical components of TRAF3 suppression of NIK protein levels and the processing of p100 to p52.

Received for publication, November 3, 2006 , and in revised form, December 11, 2006.

^* This work was supported in part by National Institutes of Health Grants RO1 AI056154, RO1 CA87924, and R01 GM57559. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Fig. S1.

¹ Supported by Clinical and Fundamental Immunology Training Grant AI07126-30.

² Supported by UCLA Medical Scientist Training Program Training Grant GM 08042.

³ Supported by a Warsaw fellowship.

⁴ A Lymphoma and Leukemia Society Scholar. To whom correspondence should be addressed: University of California, Los Angeles, Dept. of Microbiology, Immunology, and Molecular Genetics, 8-240 Factor Bldg., 10833 Le Conte Ave., Los Angeles, CA 90095. Tel.: 310-825-8896; Fax: 310-206-5553; E-mail: gcheng{at}mednet.ucla.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. M. Zapata, D. Llobet, M. Krajewska, S. Lefebvre, C. L. Kress, and J. C. Reed Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer Blood, May 7, 2009; 113(19): 4595 - 4603. [Abstract] [Full Text] [PDF]

				P. J. Alff, N. Sen, E. Gorbunova, I. N. Gavrilovskaya, and E. R. Mackow The NY-1 Hantavirus Gn Cytoplasmic Tail Coprecipitates TRAF3 and Inhibits Cellular Interferon Responses by Disrupting TBK1-TRAF3 Complex Formation J. Virol., September 15, 2008; 82(18): 9115 - 9122. [Abstract] [Full Text] [PDF]

				Y. Sasaki, D. P. Calado, E. Derudder, B. Zhang, Y. Shimizu, F. Mackay, S.-i. Nishikawa, K. Rajewsky, and M. Schmidt-Supprian NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells PNAS, August 5, 2008; 105(31): 10883 - 10888. [Abstract] [Full Text] [PDF]

				J.-S. Gatot, R. Gioia, T.-L. Chau, F. Patrascu, M. Warnier, P. Close, J.-P. Chapelle, E. Muraille, K. Brown, U. Siebenlist, et al. Lipopolysaccharide-mediated Interferon Regulatory Factor Activation Involves TBK1-IKK{epsilon}-dependent Lys63-linked Polyubiquitination and Phosphorylation of TANK/I-TRAF J. Biol. Chem., October 26, 2007; 282(43): 31131 - 31146. [Abstract] [Full Text] [PDF]